{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:27:55Z","timestamp":1787686075129,"version":"build-2784847793"},"reference-count":37,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vifor Pharma Italia SrL"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients undergoing hemodialysis with iron deficiency anemia (IDA) receiving treatment with erythropoiesis-stimulating agents (ESAs) who were intolerant or non-responsive to intravenous (i.v.) ferric gluconate (FG) (hemoglobin; Hb values &lt; 10.5 g\/dL or increase in &lt;1 g\/dL) or % transferrin saturation; TSAT of &lt;20%) in the previous 6 months were switched to i.v. ferric carboxymaltose (FCM). Changes in iron status parameters, economic and safety measures were also assessed. Seventy-seven hemodialysis patients aged 68 \u00b1 15 years were included. Erythropoietin resistance index decreased from 24.2 \u00b1 14.6 at pre-switch to 20.4 \u00b1 14.6 after 6 months of FCM treatment and Hb levels \u226510.5 g\/dL improved from 61% to 75.3% patients (p = 0.042). A 1 g\/dL increase in Hb levels was also seen in 26% of patients as well as a 37.7% increase in patients achieving &gt;20% increase in TSAT after FCM. Levels of Hb, TSAT and ferritin parameters increased during FCM treatment with a concomitant decrease in ESA. A mixed-model analysis, which also considered gender, confirmed these trends. Safety variables remained stable, no hypersensitivity reaction was recorded and only one patient reported an adverse event after FCM. FCM treatment was associated with a cost saving of 11.11 EUR\/patient\/month. These results confirm the efficacy, safety and cost-effectiveness of FCM in correcting IDA in hemodialysis patients.<\/jats:p>","DOI":"10.3390\/jcm11185284","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T01:40:13Z","timestamp":1662601213000},"page":"5284","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-9108","authenticated-orcid":false,"given":"Alberto","family":"Rosati","sequence":"first","affiliation":[{"name":"SOC Nefrologia e Dialisi, Ospedale San Giovanni di Dio, 50143 Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Conti","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Nephrology Department, Arezzo Hospital, 52100 Arezzo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Berto","sequence":"additional","affiliation":[{"name":"Regulatory Pharma Net S.r.L., 56125 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7221-0873","authenticated-orcid":false,"given":"Sabrina","family":"Molinaro","sequence":"additional","affiliation":[{"name":"National Research Council, Institute of Clinical Physiology (CNR-IFC), 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Baldini","sequence":"additional","affiliation":[{"name":"National Research Council, Institute of Clinical Physiology (CNR-IFC), 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-7147","authenticated-orcid":false,"given":"Colin Gerard","family":"Egan","sequence":"additional","affiliation":[{"name":"CE Medical Writing S.r.L.S., 56021 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Panichi","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Versilia Hospital, 55049 Lido Di Camaiore, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfg458","article-title":"Anaemia in Haemodialysis Patients of Five European Countries: Association with Morbidity and Mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of Chronic Disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ahj.2005.03.055","article-title":"Kidney Function and Anemia as Risk Factors for Coronary Heart Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"151","author":"Astor","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41687-020-00215-8","article-title":"Symptoms and Impacts in Anemia of Chronic Kidney Disease","volume":"4","author":"Mathias","year":"2020","journal-title":"J. Patient-Rep. Outcomes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/sdi.12548","article-title":"Why Is Your Patient Still Short of Breath? Understanding the Complex Pathophysiology of Dyspnea in Chronic Kidney Disease","volume":"30","author":"Salerno","year":"2017","journal-title":"Semin. Dial."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/j.1523-1755.2005.00693.x","article-title":"Anemia and Mortality in Hemodialysis Patients: Accounting for Morbidity and Treatment Variables Updated over Time","volume":"68","author":"Robinson","year":"2005","journal-title":"Kidney Int."},{"key":"ref_8","first-page":"44","article-title":"Iron Deficiency Anemia in Chronic Kidney Disease","volume":"142","author":"Schechter","year":"2019","journal-title":"AHA"},{"key":"ref_9","first-page":"93","article-title":"Impact of Inflammation on Anemia of Hemodialysis Patients Who Were under Treatment of Recombinant Human Erythropoietin","volume":"2","author":"Nasri","year":"2013","journal-title":"J. Ren. Inj. Prev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2215\/CJN.05390517","article-title":"Safety of Intravenous Iron in Dialysis","volume":"13","author":"Hougen","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_11","first-page":"13","article-title":"Safety and efficacy of intravenous administration of iron preparations","volume":"74","author":"Grzywacz","year":"2017","journal-title":"Acta Pol. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.20056","article-title":"Parenteral Iron Therapy Options","volume":"76","author":"Silverstein","year":"2004","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102178","DOI":"10.1016\/j.nano.2020.102178","article-title":"Factors Influencing Safety and Efficacy of Intravenous Iron-Carbohydrate Nanomedicines: From Production to Clinical Practice","volume":"26","author":"Nikravesh","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40265-014-0332-3","article-title":"Ferric Carboxymaltose: A Review of Its Use in Iron Deficiency","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A Comparative Study of the Physicochemical Properties of Iron Isomaltoside 1000 (Monofer), a New Intravenous Iron Preparation and Its Clinical Implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bjhh.2015.08.012","article-title":"Intravenous Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia","volume":"37","author":"Friedrisch","year":"2015","journal-title":"Rev. Bras. De Hematol. E Hemoter."},{"key":"ref_17","first-page":"362","article-title":"Pharmacokinetics, Safety and Tolerability of Intravenous Ferric Carboxymaltose: A Dose-Escalation Study in Volunteers with Mild Iron-Deficiency Anaemia","volume":"60","author":"Geisser","year":"2010","journal-title":"Arzneim.-Forsch."},{"key":"ref_18","first-page":"373","article-title":"Pharmacodynamics and Safety of Ferric Carboxymaltose: A Multiple-Dose Study in Patients with Iron-Deficiency Anaemia Secondary to a Gastrointestinal Disorder","volume":"60","author":"Geisser","year":"2010","journal-title":"Arzneim.-Forsch."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/0971-4065.144421","article-title":"The Safety and Efficacy of High Dose Ferric Carboxymaltose in Patients with Chronic Kidney Disease: A Single Center Study","volume":"25","author":"Vikrant","year":"2015","journal-title":"Indian J. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Minutolo, R., Berto, P., Liberti, M.E., Peruzzu, N., Borrelli, S., Netti, A., Garofalo, C., Conte, G., Nicola, L.D., and Vecchio, L.D. (2021). Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061322"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Toblli, J., and Di Gennaro, F. (2015). Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125528"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1038\/s41598-021-86769-z","article-title":"Ferric Carboxymaltose vs. Ferrous Sulfate for the Treatment of Anemia in Advanced Chronic Kidney Disease: An Observational Retrospective Study and Cost Analysis","volume":"11","author":"Cirillo","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: A Randomized Trial of Intravenous Ferric Carboxymaltose versus Oral Iron in Patients with Chronic Kidney Disease and Iron Deficiency Anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1093\/ndt\/gfq069","article-title":"The Safety and Efficacy of Intravenous Ferric Carboxymaltose in Anaemic Patients Undergoing Haemodialysis: A Multi-Centre, Open-Label, Clinical Study","volume":"25","author":"Covic","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ndt\/gfs528","article-title":"Intravenous Ferric Carboxymaltose versus Standard Medical Care in the Treatment of Iron Deficiency Anemia in Patients with Chronic Kidney Disease: A Randomized, Active-Controlled, Multi-Center Study","volume":"28","author":"Charytan","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hofman, J.M.G., Eisenga, M.F., Diepenbroek, A., Nolte, I.M., van Dam, B., Westerhuis, R., Bakker, S.J.L., Franssen, C.F.M., and Gaillard, C.A.J.M. (2018). Switching Iron Sucrose to Ferric Carboxymaltose Associates to Better Control of Iron Status in Hemodialysis Patients. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1045-8"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1007\/s12325-019-01089-z","article-title":"Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy","volume":"36","author":"Rognoni","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.23876\/j.krcp.20.015","article-title":"Ferric Carboxymaltose versus Ferric Gluconate in Hemodialysis Patients: Reduction of Erythropoietin Dose in 4 Years of Follow-Up","volume":"39","author":"Lacquaniti","year":"2020","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1523-1755.2005.00532.x","article-title":"Hemoglobin Cycling in Hemodialysis Patients Treated with Recombinant Human Erythropoietin","volume":"68","author":"Fishbane","year":"2005","journal-title":"Kidney Int."},{"key":"ref_30","unstructured":"Aiello, A., Berto, P., Conti, P., Panichi, V., and Rosati, A. (2022, March 15). Impatto Economico dell\u2019Utilizzo di Carbossimaltosio Ferrico Nei Pazienti in Emodialisi. Available online: https:\/\/giornaleitalianodinefrologia.it\/2020\/07\/37-s75-2020-6\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e7288","DOI":"10.1590\/1414-431x20187288","article-title":"Epoetin Alfa Resistance in Hemodialysis Patients with Chronic Kidney Disease: A Longitudinal Study","volume":"51","author":"Santos","year":"2018","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Louw, E.H., and Chothia, M.-Y. (2017). Residual Renal Function in Chronic Dialysis Is Not Associated with Reduced Erythropoietin-Stimulating Agent Dose Requirements: A Cross-Sectional Study. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0752-x"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/trf.12289","article-title":"A Multicenter, Randomized, Active-Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency Anemia","volume":"54","author":"Onken","year":"2014","journal-title":"Transfusion"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000493551","article-title":"Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data","volume":"48","author":"Macdougall","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The Pharmacokinetics and Pharmacodynamics of Iron Preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"key":"ref_36","first-page":"S93","article-title":"Structure, Chemistry, and Pharmacokinetics of Intravenous Iron Agents","volume":"15","author":"Danielson","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Rostoker, G., Lepeytre, F., Merzoug, M., Griuncelli, M., Loridon, C., Boulahia, G., and Cohen, Y. (2022). Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071408"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/18\/5284\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:25:05Z","timestamp":1760142305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/18\/5284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":37,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["jcm11185284"],"URL":"https:\/\/doi.org\/10.3390\/jcm11185284","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]}}}